Schizophrenia Research and Treatment / 2011 / Article / Tab 2 / Research Article
Randomized Controlled Trial of Clozapine and CBT for First-Episode Psychosis with Enduring Positive Symptoms: A Pilot Study Table 2 Mean outcome measure scores at baseline and weeks 12 and 24 (as means and standard deviations). Missing values were provided using multiple imputation.
𝑁
Baseline Week 12 Week 24 BPRS-P TDZ 11
1
0
.
4
±
1
.
9
9
.
3
±
2
.
5
9
.
4
±
2
.
5
TDZ+CBT 12
1
1
.
2
±
2
.
7
8
.
0
±
1
.
3
6
.
5
±
1
.
8
CLZ 14
1
1
.
8
±
2
.
2
8
.
4
±
3
.
1
8
.
7
±
2
.
5
CLZ+CBT 11
1
2
.
2
±
2
.
8
9
.
1
±
4
.
2
7
.
9
±
4
.
0
SANS TDZ 11
3
2
.
9
±
1
3
.
0
2
8
.
4
±
8
.
6
2
3
.
5
±
7
.
2
TDZ+CBT 12
3
7
.
2
±
9
.
3
2
3
.
9
±
5
.
1
∗
2
5
.
9
±
9
.
7
CLZ 14
3
5
.
4
±
1
1
.
8
2
9
.
4
±
6
.
6
2
7
.
8
±
8
.
0
CLZ+CBT 11
4
0
.
2
±
1
4
.
8
2
6
.
5
±
1
2
.
1
∗
2
4
.
9
±
1
2
.
2
BDI TDZ 11
2
4
.
0
±
6
.
5
2
2
.
9
±
6
.
7
2
2
.
2
±
6
.
7
TDZ+CBT 12
2
9
.
0
±
6
.
3
2
2
.
8
±
4
.
4
1
7
.
0
±
2
.
6
∗
CLZ 14
2
6
.
6
±
8
.
1
1
8
.
1
±
5
.
5
∗
1
8
.
6
±
4
.
9
∗
CLZ+CBT 11
2
5
.
2
±
7
.
8
2
2
.
5
±
9
.
6
2
2
.
6
±
7
.
6
CGI TDZ 11
4
.
6
±
0
.
5
3.6 ± 1.0
3
.
5
±
0
.
8
TDZ+CBT 12
4
.
8
±
0
.
9
3.5 ± 0.8
3
.
0
±
0
.
5
CLZ 14
4
.
9
±
0
.
7
3
.
6
±
0
.
9
3
.
4
±
0
.
8
CLZ+CBT 11
4
.
8
±
0
.
9
3
.
6
±
1
.
4
3
.
5
±
0
.
8
SOFAS TDZ 11
4
7
.
8
±
1
2
.
6
53.2 ± 13.8
5
5
.
2
±
1
2
.
3
TDZ+CBT 12
4
3
.
0
±
1
2
.
6
5
0
.
4
±
9
.
2
5
5
.
4
±
5
.
8
CLZ 14
4
4
.
8
±
9
.
9
5
4
.
0
±
9
.
6
5
3
.
8
±
9
.
8
CLZ+CBT 11
4
5
.
2
±
1
0
.
6
5
2
.
1
±
1
1
.
1
5
5
.
4
±
1
0
.
5
QLS TDZ 11
4
8
.
7
±
2
0
.
0
5
3
.
0
±
1
7
.
2
5
9
.
6
±
1
3
.
7
TDZ+CBT 12
4
4
.
3
±
1
4
.
2
4
9
.
8
±
1
1
.
4
4
7
.
1
±
1
3
.
1
CLZ 14
5
0
.
2
±
1
2
.
9
5
8
.
8
±
1
0
.
4
5
4
.
5
±
1
4
.
6
CLZ+CBT 11
5
4
.
8
±
1
5
.
7
5
9
.
3
±
1
1
.
9
6
3
.
3
±
1
6
.
1
∗
Statistically significant,
𝑃
≤
.
0
5
.
